Please ensure Javascript is enabled for purposes of website accessibility

3 Reasons Celgene's Investors Should Applaud the Juno Therapeutics Buyout

By Brian Feroldi - Jan 27, 2018 at 3:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Right product, right price, right time. What more can you ask for?

In case you missed it, it turns out the rumor was true. Biotech giant Celgene (CELG) recently announced that it had agreed to acquired Juno Therapeutics (JUNO) for $9 billion. This represents the company's largest acquisition in its history.

Should shareholders cheer this news, or is it possible that management just made an unforced error? Here are three reasons investors should believe in this deal.

Businessmen shaking hands and exchanging money

Image source: Getty Images.

1. Right products

Juno Therapeutics is a clinical-stage biotech that is focused on immunotherapy. Specifically, the company is working on an exciting new type of treatment called chimeric antigen receptor T-cell therapy, or CAR-T. This therapy extracts a patient's T-cells and then reprograms them to be able to identify cancer. Once complete, they are infused back into the patient's body, and they go to work on the patient's disease.

While Juno boasts a number of products in its pipeline, its crown jewel is called liso-cel, which is also called JCAR017. This CAR-T therapy holds promise to be a best-in-class treatment.

That potential "best-in-class" label is of prime importance here because, if approved, JCAR017 won't be the first CAR-T drug to hit the market. That honor actually belongs to Novartis' (NVS 1.44%) drug Kymriah. Gilead Sciences' (GILD -0.28%) also successfully crossed the finish line with a CAR-T drug called Yescarta thanks to its recent buyout of Kite Pharmaceuticals.

Thus, the competition in this space is expected to be stiff.

Why does Celgene believe JCAR017 will be able to stand out? The answer lies in the drug's data when compared to Kymriah and Yescarta:

Chart showing that JCAR017 compares favorably to Kymiriah and Yescarta.

Image source: Celgene presentation.

This chart shows that JCAR017 successfully outperformed both Yescarta and Kymriah in the two metrics that matter most to healthcare providers and patients: efficacy and safety. This suggests that JCAR017 could be the top CAR-T therapy if it wins approval. Adding the rest of Juno's pipeline to the mix is only icing on the cake.

2. Right price

Writing a check for $9 billion is a heck of a gamble, but there's an argument to be made that the company is getting Juno for a decent price.

One recent point of comparison here is Gilead's recent buyout of Kite Pharma. Gilead shelled out $11.9 billion to bring Kite into the fold, which is more than Celgene is ponying up for Juno. However, Kite had already filed Yescarta for approval when the acquisition was announced. This makes the $9 billion price tag look reasonable since JCAR017's submission is still about a year away.

Another way to think about the buyout price is to look at JCAR017's peak sales potential. Celgene's management believes the drug could eventually pull in approximately $3 billion in annual sales, which means Celgene is paying three times that figure. That's a reasonable multiple based on JCAR017's potential alone, let alone what the rest of Juno's pipeline might eventually be worth.

Overall, the evidence suggests that the $9 billion buyout price looks quite reasonable.

Colorful drugs on top of hundred dollar bills

Image source: Getty Images.

3. Right time

Why did Celgene decide to announce this deal in January of 2018? A few reasons come to mind.

First, JCAR015 has not yet been submitted to the FDA; that's expected to take place later this year. You could argue that reaching a milestone like that would have pumped the price tag even higher. Given that Yescarta and Kymriah both sailed through the FDA approval process with ease, this looks to be a slam-dunk. Buying the company ahead of that value-creating event makes sense to me.

Another factor to consider is the recent changes to the U.S. tax code. The new rules will allow Celgene to fund this deal in part with some of its international cash, which wouldn't have been as attractive of an option under the old rules. 

When combined, these factors make the timing of this deal look quite smart.

Celgene is a buy

Overall, while this deal is certainly a gamble, this shareholder thinks there is ample reason to believe this acquisition will work out favorably for investors. With shares currently trading hands at a cheap valuation -- Celgene's stock can be purchased right now for around 12 times 2018 estimated earnings -- this Fool continues to believe Celegene is a rare bargain in today's pricey market.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celgene Corporation Stock Quote
Celgene Corporation
CELG
Juno Therapeutics, Inc. Stock Quote
Juno Therapeutics, Inc.
JUNO
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$63.66 (-0.28%) $0.18
Novartis AG Stock Quote
Novartis AG
NVS
$90.71 (1.44%) $1.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.